Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, we have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific or medical investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, we manage over $1.2 billion of committed capital. LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory knowhow, and market insights. We also have strong global perspective and connections, driven by the consolidated experience of our team members overseas as well as our network of scientific advisors. By combining our China

Sinopharm Capital, under Sinopharm Group, is a professional PE company specialized in healthcare industry. The funds are managed by a team of Sinopharm Group seniors, investment bank experts and professional investors. The management team has profound understanding about the development and operation of Chinese healthcare industry and they also have rich knowledge of capital operation. Sinopharm Capital has the capability to efficiently integrate both internal and external Group resources, as well as, industry resources and capital strengths. Upholding the Group’s philosophy regarding “All for health, health for all”, Sinopharm Capital sticks to its responsibility and ambition as the industry capital leader. The fund holds the philosophy of being “faithful, professional and win-win”, and Sinopharm Capital is devoted to be the creator, explorer, integrator, and implementer of Chinese healthcare industry.

Jianxin Capital is a venture capital firm focusing on the healthcare industry including biotech, IVD, medical device, etc.The company focuses on the in-depth research in major diseases and unmet medical needs , promoting the establishment of startups with first-tier teams and technology platforms. Jianxin also provides professional insights, experience, and resources in product pipelines, team formation, application for registration, clinical trials and business development to promote the startups becoming an industry leader.Since the establishment of the company，Jianxin has invested in Eastern Biotech, Innocare, Abbisko Therapeutics, Teligene Ltd, Chipscreen, Akeso Biopharma, LP Pharma,etc which are the leaders in the industry.Jianxin Capital was awarded‘Top 100 Venture Capital Institutions’and‘Top 20 Investment Institutions in the Healthcare Sector’issued by Zero2IPO Group.

Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from secular industry transformation in China. With over US$1.3 Billion of committed capital, LVC mainly focuses on the following segments: New Consumer (Media, Entertainment and Education), Healthcare and also covers Specialty Industrials and Financial Services. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation, accelerating growth via strategic initiatives and our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds and family offices, as well as elite entrepreneurs and founders of  China's Fourtune 500 enterprises. LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management("CUAM"), one of China's top asset managers with over US$70B in AUM, is known for its industry leading research and award-winning investment records.

CICC Capital Management Co., Ltd. (“CICC Capital” or “the Firm”) is the flagship platform of China International Capital Corporation Limited (“CICC”) for its global private equitybusinesses. The Firm is committed to becoming a globally leading private equity manager with an impactful brand, a large and stable investor base, superior investment capabilities, and prudent and efficient mid-and-back offices. The Firm’s product portfolio has been expanding steadily along three dimensions – investment strategy, industry focus, and geographical area. Currently, the Firm runs government-banckedfunds investing in emerging industries, funds focusing on restructuring of traditional sectors, USD and RMB funds of funds, and USD and RMB private equity funds with variousstrategies including venture capital, growth, buyout and distressed investment. With a total AUM of around RMB300 billion and over 200 high-caliber professionals in its staff body, CICC Capital has become a leading private equity brand in China. Looking ahead, CICC Capital will continue to explore different asset classes, develop innovative business models, broaden its investment capabilities, strengthen its operation systems, and enhance the value of its brand, so as to deliver strong ruturns to the investors of its fund products over the long term.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen and Hong Kong. In 2017, Qiming Venture Partners raised its first US fund, and set up Qiming Venture Partners’ US offices in Seattle, Boston and Palo Alto. Currently Qiming Venture Partners manages seven US Dollar funds and five RMB funds with US$4 billion assets under management. Qiming Venture Partners strives to be the investor of choice for top entrepreneurs in China. Since our debut, we have backed over 310 young, fast-growing and innovative companies across China in the internet and consumer ("Intersumer"), healthcare, information technology and clean technology sectors. Over 50 of them are already listed on NYSE, NASDAQ, Shanghai Stock Exchange, Shenzhen Stock Exchange, HKEx and Gretai Securities Market or achieved exit through M&A. There are also nearly 20 portfolio companies that have been recognized as unicorns in the industry. And many of our portfolio companies are today’s most influential brands in their respective sectors, including Xiaomi (01810.HK), Cootek (CTK.US), Meituan-Dianping (03690.HK), Mogujie Inc. (MOGU.US), Meitu (01357.HK), Bilibili (Nasdaq: BILI), Tigermed (300347.SZ), Gan & Lee, Zai Lab (Nasdaq: ZLAB), Hexing (603556.SH), CSD (603903.SH), Tellgen (300642.SZ), AmoyDx (300685.SZ), Berry Genomics (000710.SZ), HyperStrong, We Doctor Group, MEGVII, UBTech, Mobike, Sinocell and WeRide.ai. Qiming Venture Partners consistently ranks among the top venture firms in terms of returns to its investors. Qiming Venture Partners drives innovation and growth of business enterprises and promotes overall industry advancement and social development. With access to our partners’ experience and global network as well as our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!

Temasek is an investment company with a net portfolio value of S$306 billion (RMB1.52t) as at 31 March 2020. Our three roles as an Investor, Institution and Steward, as defined in our Temasek Charter, shape our ethos to do well, do right and do good. Our investment philosophy is anchored around four key themes: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions. Our investment direction in Temasek is shaped by structural trends: longer lifespans, rising affluence and sustainable living drive social progress, enabled by technological solutions for sharing economies, smarter systems and a more connected world. We actively seek sustainable solutions to address present and future challenges, as we capture investment and other opportunities that help to bring about a better, smarter and more sustainable world. Temasek has had overall corporate credit ratings of Aaa/AAA by rating agencies Moody’s Investors Service and S&P Global Ratings respectively, since our inaugural credit ratings in 2004. Headquartered in Singapore, we have 11 offices around the world: Beijing, Hanoi, Mumbai, Shanghai and Singapore in Asia; and London, New York, San Francisco, Washington DC, Mexico City, and Sao Paulo outside Asia. For more information on Temasek, please visit www.temasek.com.sg For Temasek Review 2020, please visit www.temasekreview.com.sg

Hankang Capital is a venture capital firm dedicated to investing in the bio-pharmaceutical industry in China. The fund focuses on major disease areas and unmet medical needs, pays special attention to companies with outstanding management team and pioneering technical platform, and helps them become industry leaders by providing continuous investments and profound value-added services.

TF Capital focuses on investment in the life sciences industry,primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partmerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. The firm employs a diversified strategy within life.